Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

CD36 is a co-receptor for hepatitis C virus E1 protein attachment.

Cheng JJ, Li JR, Huang MH, Ma LL, Wu ZY, Jiang CC, Li WJ, Li YH, Han YX, Li H, Chen JH, Wang YX, Song DQ, Peng ZG, Jiang JD.

Sci Rep. 2016 Feb 22;6:21808. doi: 10.1038/srep21808.

2.

Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus.

Prentoe J, Serre SB, Ramirez S, Nicosia A, Gottwein JM, Bukh J.

J Virol. 2014 Feb;88(3):1725-39. doi: 10.1128/JVI.02017-13. Epub 2013 Nov 20.

3.

A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner.

Lee M, Yang J, Jo E, Lee JY, Kim HY, Bartenschlager R, Shin EC, Bae YS, Windisch MP.

Sci Rep. 2017 Mar 23;7:44676. doi: 10.1038/srep44676.

4.

Interferon alpha decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes.

Murao K, Imachi H, Yu X, Cao WM, Nishiuchi T, Chen K, Li J, Ahmed RA, Wong NC, Ishida T.

Gut. 2008 May;57(5):664-71. Epub 2007 Nov 12.

PMID:
17998316
5.

Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission.

Catanese MT, Loureiro J, Jones CT, Dorner M, von Hahn T, Rice CM.

J Virol. 2013 Aug;87(15):8282-93. doi: 10.1128/JVI.01102-13. Epub 2013 May 22.

6.

Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection.

Bocchetta S, Maillard P, Yamamoto M, Gondeau C, Douam F, Lebreton S, Lagaye S, Pol S, Helle F, Plengpanich W, Guérin M, Bourgine M, Michel ML, Lavillette D, Roingeard P, le Goff W, Budkowska A.

PLoS One. 2014 Mar 19;9(3):e92140. doi: 10.1371/journal.pone.0092140. eCollection 2014.

7.

Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert TF, Duverlie G, Séron K, Penin F, Dubuisson J.

J Virol. 2014 Sep;88(18):10584-97. doi: 10.1128/JVI.01402-14. Epub 2014 Jul 2.

8.

Characterization of hepatitis C virus particle subpopulations reveals multiple usage of the scavenger receptor BI for entry steps.

Dao Thi VL, Granier C, Zeisel MB, Guérin M, Mancip J, Granio O, Penin F, Lavillette D, Bartenschlager R, Baumert TF, Cosset FL, Dreux M.

J Biol Chem. 2012 Sep 7;287(37):31242-57. doi: 10.1074/jbc.M112.365924. Epub 2012 Jul 5.

9.

Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.

Bankwitz D, Vieyres G, Hueging K, Bitzegeio J, Doepke M, Chhatwal P, Haid S, Catanese MT, Zeisel MB, Nicosia A, Baumert TF, Kaderali L, Pietschmann T.

J Virol. 2014 Nov;88(21):12644-55. doi: 10.1128/JVI.01145-14. Epub 2014 Aug 20.

10.

Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors.

Syder AJ, Lee H, Zeisel MB, Grove J, Soulier E, Macdonald J, Chow S, Chang J, Baumert TF, McKeating JA, McKelvy J, Wong-Staal F.

J Hepatol. 2011 Jan;54(1):48-55. doi: 10.1016/j.jhep.2010.06.024. Epub 2010 Aug 21.

PMID:
20932595
11.

Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes.

Barth H, Cerino R, Arcuri M, Hoffmann M, Schürmann P, Adah MI, Gissler B, Zhao X, Ghisetti V, Lavezzo B, Blum HE, von Weizsäcker F, Vitelli A, Scarselli E, Baumert TF.

J Virol. 2005 May;79(9):5774-85.

12.

(-)-Epigallocatechin-3-gallate is a new inhibitor of hepatitis C virus entry.

Calland N, Albecka A, Belouzard S, Wychowski C, Duverlie G, Descamps V, Hober D, Dubuisson J, Rouillé Y, Séron K.

Hepatology. 2012 Mar;55(3):720-9. doi: 10.1002/hep.24803.

PMID:
22105803
13.

[Research on hepatitis C virus entry inhibitor].

Zeng Wenting, Lu X, Wang J, Jin X, Zhu J.

Bing Du Xue Bao. 2015 Jan;31(1):97-105. Review. Chinese.

PMID:
25997338
14.

Ficolin-2 inhibits hepatitis C virus infection, whereas apolipoprotein E3 mediates viral immune escape.

Zhao Y, Ren Y, Zhang X, Zhao P, Tao W, Zhong J, Li Q, Zhang XL.

J Immunol. 2014 Jul 15;193(2):783-96. doi: 10.4049/jimmunol.1302563. Epub 2014 Jun 13.

15.

Single amino acid mutation of SR-BI decreases infectivity of hepatitis C virus derived from cell culture in a cell culture model.

Gao R, Gao W, Xu G, Xu J, Ren H.

World J Gastroenterol. 2017 Jul 28;23(28):5158-5166. doi: 10.3748/wjg.v23.i28.5158.

16.

A novel small molecule inhibitor of hepatitis C virus entry.

Baldick CJ, Wichroski MJ, Pendri A, Walsh AW, Fang J, Mazzucco CE, Pokornowski KA, Rose RE, Eggers BJ, Hsu M, Zhai W, Zhai G, Gerritz SW, Poss MA, Meanwell NA, Cockett MI, Tenney DJ.

PLoS Pathog. 2010 Sep 2;6(9):e1001086. doi: 10.1371/journal.ppat.1001086.

17.

A Schisandra-Derived Compound Schizandronic Acid Inhibits Entry of Pan-HCV Genotypes into Human Hepatocytes.

Qian XJ, Zhang XL, Zhao P, Jin YS, Chen HS, Xu QQ, Ren H, Zhu SY, Tang HL, Zhu YZ, Qi ZT.

Sci Rep. 2016 Jun 2;6:27268. doi: 10.1038/srep27268.

18.

High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.

Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N.

J Biol Chem. 2005 Mar 4;280(9):7793-9. Epub 2005 Jan 4.

19.

Glucocorticosteroids increase cell entry by hepatitis C virus.

Ciesek S, Steinmann E, Iken M, Ott M, Helfritz FA, Wappler I, Manns MP, Wedemeyer H, Pietschmann T.

Gastroenterology. 2010 May;138(5):1875-84. doi: 10.1053/j.gastro.2010.02.004. Epub 2010 Feb 10.

PMID:
20152835
20.

Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV.

Jahan S, Khaliq S, Samreen B, Ijaz B, Khan M, Ahmad W, Ashfaq UA, Hassan S.

Virol J. 2011 Jun 10;8:295. doi: 10.1186/1743-422X-8-295.

Supplemental Content

Support Center